Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares Issued
Ratios

Akebia Therapeutics (AKBA) Receivables - Net (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Receivables - Net for 10 consecutive years, with $47.0 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 36.85% to $47.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.0 million through Dec 2025, up 36.85% year-over-year, with the annual reading at $47.0 million for FY2025, 36.85% up from the prior year.
  • Receivables - Net for Q4 2025 was $47.0 million at Akebia Therapeutics, down from $66.2 million in the prior quarter.
  • The five-year high for Receivables - Net was $82.0 million in Q2 2022, with the low at $18.7 million in Q1 2023.
  • Average Receivables - Net over 5 years is $40.9 million, with a median of $34.7 million recorded in 2021.
  • The sharpest move saw Receivables - Net surged 7268.71% in 2021, then tumbled 76.13% in 2023.
  • Over 5 years, Receivables - Net stood at $51.6 million in 2021, then dropped by 21.9% to $40.3 million in 2022, then fell by 2.47% to $39.3 million in 2023, then decreased by 12.53% to $34.4 million in 2024, then soared by 36.85% to $47.0 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $47.0 million, $66.2 million, and $72.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.